Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Investors Business Daily

09 Jul 2026, 17:37 UTC · 3h ago

Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

1 claim · each scored for market impact

What matters in this story

1
Arcutis Biotherapeutics (ARQT) is entering a 'buy zone' as the FDA considers expanded use for its primary skin treatment. — FDA expansion of a key product typically leads to significant revenue growth and a positive re-rating of biotech stocks.
+0.60

Which stocks this story touches

ARQT+0.90
Stock is in a buy zone with a winning streak and potential for expanded product reach and sales.
MU+0.80
Company is spearheading a chip sector surge and leading hot prospects.
AMD+0.80
Company is spearheading a chip sector surge and leading hot prospects.